Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from NICE

Breast cancer drug blocked for NHS use in England and Wales after talks collapse

National Institute for Health and Care Excellence unable to reach price agreement with manufacturers of Enhertu

The Guardian - UK

Breast cancer drug blocked for NHS use as price talks break down for third time

Nice said it was ‘extremely disappointed’ it will be unable to recommend trastuzumab deruxtecan, sold under the brand name Enhertu.

Evening Standard

Breast cancer drug blocked for NHS use as price talks break down – leaving charities ‘beyond devastated’

Nice said it was ‘extremely disappointed’ it will be unable to recommend trastuzumab deruxtecan, sold under the brand name Enhertu

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

“John Peel said we were a waste of talent and electricity… It had become de rigueur to knock us”: Emerson Lake & Palmer and the making of Brain Salad Surgery

The prog supergroup were at their creative peak when they created the 1973 epic that took the world by storm, despite the apparent hordes of critics

Louder

Players who were sent off 10 times or more

This lot have taken plenty of early baths between them...

FourFourTwo

Menopause clinics could stop female medical workers resigning, says NHS chief

Claire Low, of United Lincolnshire Teaching Hospitals Trust, was speaking at the NHS Providers’ annual conference and exhibition in Liverpool.

Evening Standard

Health chiefs target faster endometriosis diagnoses for women

Delays in diagnosis can lead to prolonged suffering, ill health and risks to fertility

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

Rangers next Europa League opposition manager bills showdown in France as 'must win'

Nice boss Franck Haise has labelled their Europa League showdown against Rangers this month a must-win game

The National (Scotland)

Hormone replacement therapy: Experts debunk the eight most common misconceptions

NICE has revised its guidelines on HRT

The Independent UK

HRT should be the 'first-line' therapy for menopause, new UK guidance confirms

The new guidance comes after a controversial draft last year suggested CBT could be on par with HRT for treating menopause symptoms

Woman & Home

HRT should be offered as first-line treatment for menopause, says Nice

Guidelines for England and Wales address criticism of earlier draft advising CBT ‘alongside or as an alternative’ to HRT

The Guardian - UK

Women with menopause symptoms ‘should be offered HRT as first treatment’

The National Institute for Health and Care Excellence announced the changes

The Independent UK

Alzheimer’s treatment donanemab is not a ‘miracle drug’ – not providing it on the NHS is the right choice

There was frustration in some corners of the media when it was announced that a new drug to slow the progression of Alzheimer’s was not going to be made available on the NHS.

The Conversation

Hundreds of blood cancer patients to benefit from new Pfizer treatment

Myeloma affects 24,000 people a year in the UK

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

Hundreds of blood cancer patients to benefit from new treatment

Elranatamab, an injection that treats myeloma, has been recommended for NHS use by the National Institute for Health and Care Excellence.

StockNews.com

3 Tech Stocks With Massive Analyst Price Target Upsides

The tech market is well-positioned for significant growth thanks to the growing adoption of emerging technologies like AI, ML, cloud computing, and ERP. Therefore, it could be wise to invest in top tech stocks NICE Ltd. (NICE), LiveRamp Holdings (RAMP), and TaskUs (TASK) with massive analyst price target upsides. Read…

The Conversation

Alzheimer’s drug approved in the UK, but it won’t be available on the NHS – here’s why

The UK’s drugs regulator – the MHRA – has approved the Alzheimer’s drug donanemab, but it won’t be available on the NHS.

The Guardian - UK

Which disease-modifying Alzheimer’s drugs are the most promising?

Many drugs in development aim to delay, slow or reverse symptoms, but which are causing the biggest stir?

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Tens of thousands of UK dementia patients to be enrolled in clinical trials

News of the £20m scheme comes as new drug for Alzheimer’s was rejected for use on NHS in England

The Independent UK

UK regulator approves second Alzheimer's drug in months but government won't pay for it

Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after an independent watchdog agency said the treatment isn’t worth the cost to taxpayers

The Independent UK

New Alzheimer’s drug rejected for NHS use – because it’s not worth the money

Alzheimer’ patients in UK left behind over regulator’s decision to reject use of new drugs

Evening Standard

Alzheimer's 'wonder drug' Donanemab blocked for use on NHS over cost concerns

Campaigners say decision is ‘frustrating setback’ for people living with disease

Evening Standard

Alzheimer’s drug rejected for widespread use by NHS spending watchdog

Donanemab is a so-called disease-modifying treatment.

Evening Standard

Donanemab – what we know about the latest Alzheimer’s drug

The drug is one of the new ‘disease modifying’ treatments for Alzheimer’s disease.

The Independent UK

Donanemab: What is the new Alzheimer’s drug rejected for use on the NHS

Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research

1 … 10 11 12 13

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.